trading today, page-42

Great thread, guys! Lots of wonderful and informative posts.

Neo - I'll hope that the market disagrees with me on this, but with some ~15,000 new diagnoses of CRC each year in Australia alone, I don't understand the "milestone" view of full recruitment for this trial, given ACL has displayed an extensive ability to collaborate with oncologists and researchers worldwide.

I similarly don't understand the market valuation of a drug in phase III clinical trials being worth nothing, let alone -10cps if the estimates above are accurate. If, as senoj put, people are currently of the opinion that our technology isn't worthwhile investing in, I don't mind - this simply means that for the moment those of us who do believe that ACL's technology has future financial merit can purchase stock relatively cheaply.

Truth be told, in the ST I'm unsure how to proceed, given talk about a cap raising. I did notice your ST Sell sentiment though, Neo.